Category - Feature

Feature

Indaptus advancing Decoy20 against metastatic solid tumors

Indaptus Therapeutics (NASDAQ:INDP) is conducting a first-in-human, dose escalation Phase 1 study of its lead compound, Decoy20, in patients with advanced metastatic solid tumors where currently approved therapies have...

February 7, 2023

Feature

Stephanie Willerth talks up award winning bioink start-up

As CEO and co-founder of closely-held Axolotl Biosciences, Stephanie Willerth, Ph.D., also is a full professor of biomedical engineering at the University of Victoria, British Columbia, where she runs a research lab...

January 31, 2023

Feature

Azura targeting ophthalmic keratolytics for ocular surface diseases

After posting positive Phase 2b results in November, Azura Ophthalmics plans to launch a Phase 3 registration trial in mid-2023 with its lead ointment, AZR-MD-001, for the treatment of meibomian gland dysfunction (MGD)...

January 24, 2023

Feature

Reneo targeting rare genetic mitochondrial diseases with unmet need

Reneo Pharmaceuticals (NASDAQ:RPHM) is conducting a pivotal Phase 2b clinical trial with its lead asset, REN001, in a rare genetic disease that predominately affects skeletal muscle and reduces life expectancy, with...

January 17, 2023

Feature

Theralase advances pivotal clinical study of photo dynamic therapy to treat bladder cancer

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) expects to complete enrollment and primary study treatment in early 2024 of a Phase 2 pivotal clinical study for non-muscle invasive bladder cancer (NMIBC) with its light...

January 3, 2023

Feature

OcuTerra advancing eye drop for earlier treatment of diabetic retinopathy

Closely-held OcuTerra Therapeutics is conducting a Phase 2 clinical study of a novel eye drop for earlier, non-invasive treatment of patients with moderate-to-severe diabetic retinopathy to preserve vision.

December 13, 2022

Feature

Avidity Biosciences developing new class of RNA therapeutics

Avidity Biosciences (NASDAQ:RNA) is developing a novel approach for the delivery of RNA therapeutics with a new class, known as antibody oligonucleotide conjugates (AOCs), with an initial focus on skeletal muscle...

December 6, 2022

Feature

Bolt pioneering new approach to cancer immunotherapy

Bolt Biotherapeutics (NASDAQ:BOLT) is developing tumor-targeting therapies that leverage the power of basic components of the innate and adaptive immune systems to attack the tumor microenvironment.

November 29, 2022

Feature

Kinaset developing dry powder inhalation therapy for severe asthma

Closely-held Kinaset Therapeutics is developing a less invasive and potentially more cost-effective dry power inhalation alternative to currently approved injectable biologicals used in the treatment of severe asthma.

November 22, 2022

Feature

MAIA telomere-targeting technology aiming at therapy-resistant tumors

MAIA Biotechnology (NYSE American:MAIA) is developing a telomere-targeting immunotherapy, THIO, with a dual mechanism of action, that can be used in sequential combination with existing immune therapies to target cancer.

November 15, 2022

Category - Feature

Subscribe